Glucovance

Glucovance is a prescription oral medication that combines metformin hydrochloride and glibenclamide in a single tablet. It belongs to the biguanide and sulfonylurea drug classes and is marketed in the European Union. The product contains both active ingredients at doses that are formulated to work together, although specific strength information is not disclosed. Glucovance is intended for adult patients with type 2 diabetes mellitus treatment.

Glucovance is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

- As monotherapy when metformin alone does not achieve glycemic targets. - In combination with other oral antidiabetic agents to improve overall glucose control. - To reduce fasting plasma glucose levels. - To lower post‑prandial glucose excursions. - As part of a comprehensive diabetes management plan that includes lifestyle modification. - To assist in achieving HbA1c targets when combined therapy is required. - To provide a convenient fixed‑dose option that may improve medication adherence.

Glucovance, like other antidiabetic agents, may cause a range of adverse effects that vary in frequency and severity.

Common: - Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea. - Mild hypoglycemia, especially when meals are skipped or dosing is high. - Weight gain or modest increase in body weight. - Skin reactions like rash or itching. - Transient headache or dizziness. - Mild elevation of serum creatinine indicating temporary kidney function change.

Serious: - Severe hypoglycemia with confusion, loss of consciousness, or seizures. - Lactic acidosis, a rare but life‑threatening condition marked by rapid breathing and muscle pain. - Hepatotoxicity presenting as jaundice, elevated liver enzymes, or hepatic failure. - Allergic anaphylactic reaction with swelling, breathing difficulty, or hives.

When prescribing Glucovance, clinicians should evaluate patient-specific factors and monitor for conditions that could increase the risk of adverse outcomes.

- Assess renal function before initiation and periodically thereafter, as metformin accumulation can occur in impaired kidneys. - Use caution in patients with a history of cardiovascular disease, as sulfonylureas may affect cardiac risk. - Monitor for signs of lactic acidosis, especially in patients with liver disease, alcohol abuse, or severe infection. - Educate patients on recognizing hypoglycemia symptoms and the importance of consistent meal patterns. - Consider dose adjustment or discontinuation during pregnancy or lactation, pending professional guidance. - Review concomitant medications that may potentiate hypoglycemia or affect metformin clearance.

Glucovance can interact with several medicines, affecting blood glucose levels or the pharmacokinetics of its components.

Avoid: - Other sulfonylureas or meglitinides, which may cause additive hypoglycemia. - Iodinated contrast agents used for imaging in patients with renal impairment, due to risk of metformin‑associated lactic acidosis. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can increase glibenclamide concentrations.

Use with caution: - Renal‑clearing drugs such as cimetidine or trimethoprim, which may raise metformin levels. - Beta‑blockers, which can mask hypoglycemia symptoms. - ACE inhibitors or ARBs, which may affect renal function and necessitate closer monitoring. - Thiazide diuretics, which can increase blood glucose and require dose evaluation.